Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea

BACKGROUND/AIMS: Sunitinib is an oral multitargeted tyrosine kinase inhibitor used mainly for the treatment of metastatic renal cell carcinoma. The renal adverse effects (RAEs) of sunitinib have not been investigated. The aim of this study was to determine the incidence and risk factors of RAEs (pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Baek, Seon Ha, Kim, Hyunsuk, Lee, Jeonghwan, Kim, Dong Ki, Oh, Kook-Hwan, Kim, Yon Su, Han, Jin Suk, Kim, Tae Min, Lee, Se-Hoon, Joo, Kwon-Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932394/
https://www.ncbi.nlm.nih.gov/pubmed/24574832
http://dx.doi.org/10.3904/kjim.2014.29.1.40

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932394/
https://www.ncbi.nlm.nih.gov/pubmed/24574832
http://dx.doi.org/10.3904/kjim.2014.29.1.40

Ejemplares similares